Clinical endpoints in trials of chemoradiation for patients with anal cancer.

@article{GlynneJones2017ClinicalEI,
  title={Clinical endpoints in trials of chemoradiation for patients with anal cancer.},
  author={Robert Glynne-Jones and Richard R. Adams and Andre R. S. Lopes and Helen M Meadows},
  journal={The Lancet. Oncology},
  year={2017},
  volume={18 4},
  pages={
          e218-e227
        }
}
This Review examines the reporting of endpoints in randomised controlled trials (RCTs) of radical chemoradiation for treatment of squamous cell carcinoma of the anus. The types, frequency, and definitions of clinical primary and secondary endpoints, and patient-reported outcome measures, reported in the methods and results sections of papers (and protocols, if available) were examined. Only six published RCTs comprising 2877 patients were identified. Primary outcome measures varied across the… CONTINUE READING
BETA
2
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 50 REFERENCES

Progression-free survival: helpful biomarker or clinically meaningless end point?

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015

Similar Papers

Loading similar papers…